TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Reduction in Dose of Systemic Corticosteroid or Other Immunosuppressive Therapy by at Least 50%
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Control of Ocular Inflammation, as Judged on Clinical Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life - change
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean of the Absolute Values of CSRT Difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under plasma concentration-time curve (AUC (0-inf))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline stiffness parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from Baseline viscoelastic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cardiac global longitudinal strain (GLS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: number of antihypertensive medications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: duration of hospitalization for all cause
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: hospitalization for cardiovascular disease
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Faecal calprotectin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants With Serum Creatinine Event of Grade 1 or Higher
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Participants With Decrease in Absolute Bone Mineral Density (BMD) From Baseline to Week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Participants With Unprotected Sex Acts
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Changes in IgG serum concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in IgM serum concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Physical functional impairment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pneumothorax
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Exposure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of composite liver-related events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Echocardiographic assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change in medication adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: IIEF-ED Domain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in home environment design for wellness
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Six-month progression-free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: AF Recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tumor necrosis factor-α (TNF-α)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Myeloperoxidase (MPO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Survival to Pump removal
Endpoint domain: Mortality/survival
Primary endpoint: Change in Serum N-acyl-phosphatidylethanolamine (NAPE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sensitivity of self-collected HPV swabs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of self-collected HPV swabs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Flow-Mediated Dilation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Glomerular Filtration Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Participants With Hospital Stay Longer Than 48 Hours
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Composite of Progression of AKI, Inpatient Dialysis, or Inpatient Death
Endpoint domain: Mortality/survival
Primary endpoint: Toxicity Grade
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Glycated Hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Profile of Mood States (POMS) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Visual Analogue Scale (VAS) scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Snaith-Hamilton Pleasure Scale (SHAPS) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Montgomery-Asberg Depression Rating Scale (MADRS) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement of disease activity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety (complications and all lead-related adverse events)
Endpoint domain: Adverse events/effects
Primary endpoint: efficacy (pacing and sensing)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular risk factors and diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants With Back Pain Improvement at 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of Participants With Functional Disability Improvement at 12 Months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Absence of Device Related Subsequent Interventions or Re-treatment at the Study Treated Levels
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: S. aureus clearance from whole blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: 100-day Non-relapse Mortality (NRM)
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Device or Procedure-related Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: KM Rate of Freedom From Atrial Fibrillation, Atrial Flutter or Atrial Tachycardia Recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Response rate of tumor size reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Early Complications number
Endpoint domain: Adverse events/effects
Primary endpoint: Number of veins identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alcohol Use Identification Test (AUDIT)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hot Flash Activity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AF ablation success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of AIR001
Endpoint domain: Adverse events/effects
Primary endpoint: Composite PK for Plasma Nitrite and Nitrate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS (Visual Analogue Scale)
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: SPADI (Shoulder Pain and Disability Index)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of Participants Achieving 20% Improvement in ACR Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change From Baseline in the Nonmotor Symptom Severity Scale (NMSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact (Immediate Post-concussion Assessment and Cognitive Testing)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychomotor Vigilance Task (PVT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in high dose IFN therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Loneliness Scale for the Elderly
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Subjective Happiness Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence Rate of FVIII Inhibitors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of days with no heart burn
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of catheter related blood stream infections (CRBSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of CRBSI/1000 CVC days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of CVCs removed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: intensity of individual pain episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Triglyceride lowering effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time on initial adjuvant treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numbers of therapy cycles of initial adjuvant treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Objective Radiographic Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Irritation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Intraocular Pressure From Baseline to Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change in Central Retinal Thickness (CRT) for Study Eye From Baseline (Day 0) to Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Headache Impact Test-6 (HIT-6)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Number of Participants With 30% or More Deterioration in Triple Timed Up & Go (3TUG) Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Change in Glycosylated Haemoglobin A1c (HbA1c) Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of z-score weight at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ventricular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Smoking cessation validated by CO exhale test<5 ppm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Total antimicrobial pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in visual analogue scale pain intensity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of BMX-010 in Treatment of Acne Vulgaris
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Maximum observed concentration (Cmax) of Astatine 211
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUC) of astatine 211 from time of dosing to 48 hrs after dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicity: hematology, liver, kidney, thyroid function
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Mean Sitting Diastolic Blood Pressure (msDBP) During the Core Phase of the Study
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Mean Sitting Diastolic Blood Pressure (msDBP) During the Extension Phase of the Study
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in AF Burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in serum ketone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of Serious Bacterial Infection (SBI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Participants With a Physician Global Assessment (PGA) Score ≤1
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: sway index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cognitive-motor interference (CMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incremental direct costs due to infection
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUC (0-24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histologic complete response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Frequency of Adverse Events/Lab Abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Length of Survival (LOS)
Endpoint domain: Mortality/survival
Primary endpoint: Age of Ventilator Dependence (AVD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Plasma concentrations of CLS001
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of study
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Comparative clinical effectiveness of COPD treatments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of current COPD treatments
Endpoint domain: Adverse events/effects
Primary endpoint: Cost effectiveness of COPD treatments
Endpoint domain: Resource use
Primary endpoint: Reduction of hypersensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Numeric Pain Rating Scale (NPRS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean AM Blood Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 4-week continuous quit rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Plasma Concentrations of Inorganic Pyrophosphate (PPi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total pain reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: wound surface area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of bacteria in wound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Post discharge adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: number of participants with treatment-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Pain Scores on the Visual Analog Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammatory Biomarkers in Serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: regeneration of taste
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of Allogenic Blood Product Transfusion
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of seroconverters with resistance mutations
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of seroconverters with signs/symptoms at or before seroconversion
Endpoint domain: Adverse events/effects
Primary endpoint: Pure Tone Average (PTA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Hearing outcomes
Primary endpoint: Air-Bone Gap (A-B Gap)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Hearing outcomes
Primary endpoint: Remission of type 2 diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fasting blood glucose level < 7.0 mmol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HbA1c < 6.5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ischemic event
Endpoint domain: Mortality/survival
Primary endpoint: Time to TDF discontinuation after diagnosis of Fanconi syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to confirmed resolution of Fanconi syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Force Platform at 4 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Timed Up&Go at 4 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Step test at 4 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Box & Blocks Test from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Frontal Assessment Battery (FAB) score from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Intrinsic Motivation Inventory (IMI) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Knee Society scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants that receive a flu shot
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Malignant Transformation of Oral Epithelial Dysplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change of Abundance of Specific Oral Microbes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: graft loss resulting in death or re-transplantation
Endpoint domain: Mortality/survival
Primary endpoint: pain caused by the injections
Endpoint domain: Adverse events/effects
Primary endpoint: Composite of Major and Clinically Relevant Non-Major (CRNM) Bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Symptomatic and Asymptomatic Recurrent Venous Thromboembolism (VTE) and VTE-Related Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Disease control measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percutaneous revascularization risk
Endpoint domain: Adverse events/effects
Primary endpoint: Central Venous Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pulmonary Arterial Mean Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fat percentage by dual-energy x-ray absorptiometry (DEXA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reverse Cholesterol Transport of HDL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of painful disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glutathione concentration in umbilical cord
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glutathione synthesis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: PROMIS Pain Interference
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement of absolute lymphocyte count (ALC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Identification of different bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Back Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Function as Measured by the Oswestry Disability Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Quality of Life as Measured by the PCS Subscale of the SF-12 Survey
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Annual Change in Percent Predicted Forced Vital Capacity (ppFVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Plasma Bivalirudin Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined Symptom and Medication Score (SMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fracture union
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Constant and Murley scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Pain Intensity Rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose corrected trough concentration of lamotrigine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deaths Over 12 Treatment Cycles
Endpoint domain: Mortality/survival